| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Efficacy and safety of prescription omega-3 fatty acids for the prevention of recurrent symptomatic atrial fibrillation: a randomized controlled trial.
|
JAMA
|
2010
|
2.68
|
|
2
|
Autonomic nervous system influences on QT interval in normal subjects.
|
J Am Coll Cardiol
|
2002
|
1.53
|
|
3
|
Comparative effectiveness of warfarin and new anticoagulants.
|
Ann Intern Med
|
2013
|
0.97
|
|
4
|
Warfarin and aspirin use in atrial fibrillation among practicing cardiologist (from the AFFECTS Registry).
|
Am J Cardiol
|
2010
|
0.88
|
|
5
|
Efficacy and safety of prescription omega-3-acid ethyl esters for the prevention of recurrent symptomatic atrial fibrillation: a prospective study.
|
Am Heart J
|
2009
|
0.86
|
|
6
|
Provider specialty and atrial fibrillation treatment strategies in United States community practice: findings from the ORBIT-AF registry.
|
J Am Heart Assoc
|
2013
|
0.81
|
|
7
|
Drug therapy for atrial fibrillation: what will its role be in the era of increasing use of catheter ablation?
|
Pacing Clin Electrophysiol
|
2009
|
0.77
|
|
8
|
Autonomic modulation of the u wave during sympathomimetic stimulation and vagal inhibition in normal individuals.
|
Pacing Clin Electrophysiol
|
2004
|
0.77
|
|
9
|
New antiarrhythmic drugs for establishing sinus rhythm in atrial fibrillation: what are our therapies likely to be by 2010 and beyond?
|
Am Heart J
|
2007
|
0.76
|
|
10
|
Device therapies in the post-myocardial infarction patient with left ventricular dysfunction.
|
Am J Cardiol
|
2008
|
0.75
|
|
11
|
Equivalence of generic and brand-name drugs for cardiovascular disease.
|
JAMA
|
2009
|
0.75
|
|
12
|
Letter by Reiffel regarding article, "Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) trial".
|
Circulation
|
2012
|
0.75
|
|
13
|
Letter by Reiffel regarding article, "Acute pharmacological conversion of atrial fibrillation to sinus rhythm".
|
Circulation
|
2009
|
0.75
|
|
14
|
An important indirect drug interaction between dronedarone and warfarin that may be extrapolated to other drugs that can alter gastrointestinal function.
|
Am Heart J
|
2011
|
0.75
|
|
15
|
Ibutilide as a Torsade de Pointes Stress Test.
|
J Am Coll Cardiol
|
2016
|
0.75
|
|
16
|
Dabigatran: comparison to warfarin, pathway to approval, and practical guidelines for use.
|
J Cardiovasc Pharmacol Ther
|
2012
|
0.75
|
|
17
|
ECG Response: Can You Make The Correct Morphology, Pathology, and Rhythm Diagnoses?
|
Circulation
|
2016
|
0.75
|
|
18
|
Frequency of serious arrhythmias detected with ambulatory cardiac telemetry.
|
Am J Cardiol
|
2010
|
0.75
|
|
19
|
ECG Challenge: Can You Make the Correct Morphology, Pathology, and Rhythm Diagnoses?
|
Circulation
|
2016
|
0.75
|
|
20
|
A most unusual pacemaker.
|
Pacing Clin Electrophysiol
|
2011
|
0.75
|
|
21
|
Cross-trial comparisons: a source of confusion, use, or both in the management of patients with atrial fibrillation?
|
Am Heart J
|
2013
|
0.75
|
|
22
|
Dronedarone For Atrial Fibrillation: Unbridled Enthusiasm Or Just Another Small Step Forward?
|
J Atr Fibrillation
|
2009
|
0.75
|